Comparison Chart Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 04:00:00 2026-07-28 pm EDT			5-day change	1st Jan Change
2.870 ^USD	+1.77%		-3.69%	+4.36%

Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	PERSPECTIVE THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+1.77%	-3.69%	+4.36%	-30.34%	-59.35%	327M